news
Moderna applies for regulatory authorisation for COVID-19 vaccine
The company has submitted for Emergency Use Authorization in the US and Conditional Marketing Authorization in Europe for its mRNA-1273 vaccine against COVID-19.
List view / Grid view
Moderna
news
UK secures total of 357 million doses of various COVID-19 vaccines
After purchasing an additional two million doses of Moderna's COVID-19 vaccine, the UK will now receive a total of 357 million doses of vaccines from seven developers.
news
EU secures 80 million doses of Moderna COVID-19 vaccine
The European Commission and Moderna have agreed that the company will supply at least 80 million doses of mRNA-1273, the company's COVID-19 vaccine candidate.
news
EMA initiates rolling review of Moderna’s COVID-19 vaccine
The rolling review will shorten the approval timeframe by evaluating data on the safety, efficacy and quality of the mRNA-1273 vaccine as it becomes available.
news
Moderna’s COVID-19 vaccine is 94.5 percent effective, according to interim analysis
The analysis reveals that mRNA-1273 was generally well tolerated and prevented COVID-19 with an efficacy of 94.5 percent in a Phase III study.
news
Takeda to supply Japan with Moderna’s COVID-19 vaccine
Takeda will import and distribute 50 million doses of the mRNA-1273 vaccine candidate under an agreement with Moderna and Government of Japan.
news
COVID-19 vaccine candidate well-tolerated in older adults
The experimental COVID-19 vaccine, mRNA-1273, was well-tolerated and elicited a strong immune response in older adults during a Phase I trial.
news
Moderna to supply US with initial 100 million doses of COVID-19 vaccine
Moderna will supply the US with at least 100 million doses of mRNA-1273, its COVID-19 vaccine candidate currently in Phase III clinical trials.
news
Moderna initiates Phase III trial of COVID-19 vaccine candidate
The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
news
Moderna and Catalent to collaborate on COVID-19 vaccine manufacture
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.
news
FDA grants Fast Track Designation to Moderna’s COVID-19 vaccine
The US FDA has given Fast Track Designation to Moderna's mRNA vaccine candidate, mRNA-1273, designed to protect against COVID-19.
article
COVID-19: a wakeup call?
It appears the world was unprepared for a novel coronavirus, despite historical precedents. Dave Elder provides some insight on the disease and what the pharmaceutical community is doing to tackle the pandemic.
news
BARDA to give Moderna up to $483 million for COVID-19 vaccine development
The US Biomedical Advanced Research and Development Authority (BARDA) will fund Moderna’s COVID-19 vaccine candidate mRNA-1273 through Phase II and III clinical trials to FDA licensure.
article
Potential COVID-19 therapeutics currently in development
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
news
COVID-19 update: therapeutic and regulatory developments
European Pharmaceutical Review rounds up the latest news surrounding COVID-19, including a vaccine moving to clinical trials and the FDA's update on Chinese import inspections.
